Key facts
- Anivive’s last known valuation is $295.0M (Aug 2021).
- It has raised $65.0M; the latest was Later Stage VC ($20.0M) in Jan 2025.
- Notable investors include Arizona State University, LEONID, Tech Launch Arizona, U.S. Department of Health and Human Services, U.S. Food and Drug Administration — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Anivive
- ·The full record, as it builds
Funding rounds
No funding rounds for Anivive are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anivive
Operator of a veterinary therapeutics technology platform intended to offer pet medicines focused on reshaping pet healthcare. The company's technology includes innovative and promising new therapies, an anti-fungal vaccine for pets, and an oral selective inhibitor of a nuclear export compound for the treatment of canine cancers, including lymphoma, enabling pets to live a disease-free life.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Long Beach, CA, United States
- Founded
- 2015
- Employees
- 26
- Website
- anivive.com/
- Ownership
- Privately Held (backing)
Anivive doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anivive shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anivive in its N-PORT filings yet. We sweep new filings monthly.